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A 12 month survey of candidaemia in Scotland, UK, in which every Scottish hospital laboratory
submitted all blood isolates of yeasts for identification, strain typing and susceptibility testing,
provided 300 isolates from 242 patients, generating incidence data of 4.8 cases per 100000
population per year and 5.9 cases per 100000 acute occupied bed days; 27.9% of cases
occurred in intensive care units. More than half the patients with candidaemia had an underlying
disease involving the abdomen, 78% had an indwelling intravenous catheter, 62% had suffered a
bacterial infection within the 2 weeks prior to candidaemia and 37% had undergone a
laparotomy. Candida albicans was the infecting species in 50% of cases, followed by Candida
glabrata (21%) and Candida parapsilosis (12%). Seven cases of candidaemia were caused by
Candida dubliniensis, which was more prevalent even than Candida lusitaniae and Candida
tropicalis (six cases each). Among C. glabrata isolates, 55% showed reduced susceptibility to
fluconazole, but azole resistance among other species was extremely low. Multilocus sequence
typing showed isolates with high similarity came from different hospitals across the country, and
many different types came from the hospitals that submitted the most isolates, indicating no
tendency towards hospital-specific endemic strains. Multiple isolates of C. albicans and C.
glabrata from individual patients were of the same strain type with single exceptions for each
species. The high prevalence of candidaemia in Scotland, relative to other population-based
European studies, and the high level of reduced fluconazole susceptibility of Scottish C. glabrata
isolates warrant continued future surveillance of invasive Candida infections.
INTRODUCTION
Bloodstream infections with Candida species arise in many
different types of patient. Reports in recent years have
varied between claiming an increase, a decrease and no
change in incidence of candidaemia, but a recent review
found the majority of surveys showed a stable incidence
trend (Morgan, 2005) and very large North American
studies point to a decrease in incidence of, and mortality
due to, candidaemia through the 1990s (McNeil et al.,
2001; Trick et al., 2002).
Few of the many surveys of candidaemia are population-
based for a whole country or a geographical region. Surveys
in different regions of the USA have shown dramatic
differences in incidence, with an estimated 6 cases per 10
5
population in Iowa (Diekema et al., 2002), 7 cases per 10
5
population in Connecticut (Hajjeh et al., 2004), 8 cases per
10
5 population in Atlanta and San Francisco (Kao et al.,
1999), and 24 cases per 10
5 population in Baltimore
(Hajjeh et al., 2004). Outside the USA, population-based
estimates of candidaemia incidence have mainly been
much lower, ranging between 1.1 and 4.9 cases per 10
5
population in surveys from Canada (Laupland et al., 2005),
Finland (Poikonen et al., 2003), Iceland (Asmundsdottir
et al., 2002) and Norway (Sandven et al., 2006). The
striking exception is Denmark, with an incidence of 11 cases
per 10
5 population (Arendrup et al., 2005). In the UK, a
recent study based in 6 sentinel hospitals reported a rate of
3.34 cases of candidaemia per 100000 bed days (Kibbler
et al., 2003).
Reasons for these incidence variations are unclear. One
very recent study of Italian intensive care units (ICUs)
Abbreviations: AOBD, acute occupied bed day; DST, diploid sequence
type; ICU, intensive care unit; IV, intravenous; MLST, multilocus sequence
typing; OBD, occupied bed day; PMN, polymorphonuclear neutrophil; S-
DD, susceptible dose-dependent; ST, sequence type.
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of candidaemia and defined daily doses of fluconazole
(Bassetti et al., 2006); however, the annual numbers are
small, and the rise in incidence comes mainly from cases
due to Candida albicans and Candida parapsilosis, rather
than from species that typically show reduced flucona-
zole susceptibility (Candida glabrata, Candida krusei).
Fluconazole prophylaxis has often been cited as a trigger
for the emergence of low-susceptibility Candida species;
the earliest example of such data was published more than
10 years ago (Price et al., 1994). However, only C. glabrata
fungaemia showed a statistically proven rise in incidence
(as opposed to prevalence) in a survey that covered more
than 3 million ICU patients over a 10 year period (Trick
et al., 2002) and an antifungal surveillance programme
involving more than 13000 bloodstream isolates of
Candida species from 1992 to 2004 continues to show C.
krusei as the most fluconazole-resistant Candida species,
yet it accounts for only 2.3% of all isolates (Pfaller et al.,
2006).
Changes in the medical and surgical management of
patients over the past 15 years are likely to influence their
vulnerability to haematogenous dissemination of Candida
species that form part of their commensal flora. The
mechanisms whereby procedures and agents used to
manage patients with haematological malignancies predis-
pose to dissemination of gastrointestinal fungal commen-
sals have been described in fine detail (Blijlevens et al.,
2002). However, other gastrointestinal insults that arise as a
consequence of abdominal surgery and ICU management
procedures may have led to the now well-known shift of
candidaemia away from its former association with
neutropenia and into many other patient groups (Hajjeh
et al., 2004).
No published surveys of candidaemia have ever involved
patients in Scotland, so we undertook a pilot, 1 year study
of all cases of candidaemia identified by a positive blood
culture for a Candida species. The antifungal susceptibil-
ities of isolates were determined, and the epidemiological
relationships of isolates of C. albicans, C. glabrata and
Candida tropicalis were assessed by multilocus sequence
typing (MLST).
METHODS
Microbiology laboratories in all Scottish hospitals undertook to send
to the Aberdeen Fungal Group laboratory subcultures of all yeasts
isolated from blood cultures during the period March 1st 2005 to
February 28th 2006. Isolates from catheter tips were not included. A
short pro forma was provided to gather information on the patient
with a yeast-positive blood culture, when this was available. The
information requested included the patient’s age, sex, main under-
lying condition and neutrophil count at the time of the positive blood
culture, and the presence or absence of an indwelling catheter,
whether or not the patient was receiving total parenteral nutrition or
corticosteroid therapy, other infections documented, and any
antibacterial or antifungal therapy given in the 2 weeks before blood
culture, the therapy given for the present episode of fungaemia and
whether or not the intravenous (IV) catheter was removed as part of
antifungal treatment. While full information was not available for all
patients, the co-operation and enthusiasm of the participating
physicians and laboratories was very high, and clinical data were
obtained for the majority of cases. Most acute hospitals in Scotland
participated and we are confident that very few instances of
candidaemia were missed during the study period.
The isolates received were streaked to single colonies on CHROMagar
Candida plates to facilitate detection of mixed cultures, and provide
presumptive identification of C. albicans/Candida dubliniensis, C.
krusei and C. tropicalis (Odds & Bernaerts, 1994). C. albicans was
differentiated from C. dubliniensis by PCR determining the position
of the ITS1 intron (McCullough et al., 1999). Other species were
identified by standard morphological and physiological criteria. C.
parapsilosis isolates were confirmed as C. parapsilosis, Candida
metapsilosis or Candida orthopsilosis by PCR and restriction digestion
(Tavanti et al., 2005a). Isolates of C. albicans, C. glabrata and C.
tropicalis were further characterized by MLST (Bougnoux et al., 2003;
Dodgson et al., 2003; Tavanti et al., 2005c). Isolates were
characterized by their diploid sequence type (DST) for C. albicans
and C. tropicalis, and by their (haploid) sequence type (ST) for C.
glabrata. C. albicans isolates were assigned to MLST clades by
reference to a UPGMA dendrogram drawn for the current database of
1391 C. albicans isolates (Odds et al., 2007). Relatedness of C. albicans
isolates that differed from each other in only one of the seven MLST
gene loci was determined by eBURST analysis (Feil et al., 2004) and
isolates found to be related by this analysis were referred to as clonal
clusters.
Antifungal susceptibilities of the isolates were measured by micro-
dilution plate testing as previously described (Odds et al., 1995). This
method, including spectrophotometric determination of MIC end
points from dose-response curves, is essentially the same as the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) antifungal methodology (Cuenca-Estrella et al., 2002b,
2003, 2005) and all MICs were read at 24 h in conformity with
EUCAST norms. Our method (Odds et al., 1995), and the EUCAST
method (Cuenca-Estrella et al., 2002b), have been shown to give
MICs for triazole antifungal agents that correspond well with those
determined by the Clinical and Laboratory Standards Institute
method (NCCLS, 2002).
RESULTS
Candidaemia: incidence and demographics
Over the course of 1 year, 300 yeasts were isolated in blood
cultures from 242 patients in 19 Scottish hospitals. Two or
more positive cultures on different days were obtained
from twenty-three patients. In 19 of these instances, the
multiple isolates were obtained within a maximum of
12 days apart (median 4 days, mode 1 day) and were
regarded as single episodes of candidaemia. For the
remaining 4 patients, second positive blood cultures were
obtained 21, 24, 37 and 44 days apart. While these may
therefore be regarded as separate episodes or cases of
candidaemia, in all four instances the second isolate was
either the same species (two patients) or the same MLST
strain type (two patients) as the first isolate, suggesting
relapse or recurrence of a single instance of candidaemia,
rather than a newly incident case. Data from the most
recent (2001) census (http://www.scrol.gov.uk/scrol/
common/home.jsp) list the population of Scotland at
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in Scotland can therefore be calculated as 4.8 per 100000
population per year. Data from the Information and
Statistics Division, Common Services Agency, National
Health Service Scotland, indicate 4100095 acute occupied
bed days (AOBDs) for the period of the study. This results
in a figure of 5.9 cases of candidaemia per 100000 AOBDs.
Demographic and clinical information on the patients with
candidaemia is summarized in Table 1. No information
was provided for two patients; for the remainder, the
information forms listed at least one item of data
concerning the candidaemic patient. There were approxi-
mately equal numbers of male and female patients with
candidaemia (Table 1); the 52:48 ratio of females to males
matches the sex distribution of the population in the most
recent Scottish census (http://www.scrol.gov.uk/scrol/
common/home.jsp). Most cases of candidaemia arose in
patients above the age of 50 years; there were 13 cases in
children below the age of 5 (Table 1), of whom 4 were
neonates (the median age of the paediatric patients was
2 years). Severe neutropenia [polymorphonuclear neutro-
phil (PMN) count ,0.5610
9 cells ml
21] was very
uncommon among the patients with candidaemia where
the information was available; 95% of the patients had
neutrophil counts within normal limits (Table 1).
The presence of an indwelling IV catheter and recent
treatment with antibacterial agents (most of which were
broad-spectrum agents or combinations of narrow-spec-
trum agents) were factors common to three-quarters of the
patients (Table 1). Almost 30% of the patients were
receiving total parenteral nutrition at the time of
candidaemia, but only 12% were undergoing treatment
with corticosteroids (Table 1). Sixty-three cases of
candidaemia (27.9%) were detected in patients receiving
intensive care. During the study period there were 49805
occupied bed days (OBDs) on ICUs, equating to a rate of
1.26 cases of candidaemia per 1000 ICU OBDs.
Underlying diseases in patients with candidaemia
Tables of underlying and predisposing factors in patients
with candidaemia commonly represent patients with
multiple factors more than once. To provide a clear idea
of the types of conditions associated with candidaemia,
Table 2 presents information on underlying diseases
(excluding children less than 5 years old) by grouping
patients according to the body system primarily affected by
the underlying disease, where this could be determined.
Diseases affecting abdominal systems, particularly the
gastrointestinal tract, dominated the list of underlying
diseases (Table 2). Recent abdominal surgery had been
documented for 37% of the patients overall; the 10 cases
listed under this heading in Table 2 were those for which
no other information was available. Moreover, 12.6% of
patients had solid tumours or sarcomas, making solid
tumours a more common underlying condition than
haematological malignancy in this set of patients.
Table 1. Selected demographic and clinical factors for
patients with candidaemia
Factor (no. of patients assessable) No. of
patients
Sex (n5236)
Male 114 (48.3%)
Female 122 (51.7%)
Age (years) (n5237)
,5 13 (5.5%)
5–29 8 (3.4%)
30–49 44 (18.6%)
50–69 87 (36.7%)
70+ 85 (35.9%)
PMN count (n5192)
,0.5610
9 cells l
21 7 (3.7%)
0.5–1.0610
9 cells l
21 0( 0% )
1.0–1.5610
9 cells l
21 3 (1.6%)
.1.5610
9 cells l
21 182 (94.8%)
IV catheter in situ (n5223) 175 (78.5%)
Receiving total parenteral nutrition (n5201) 59 (29.4%)
Receiving corticosteroids (n5190) 22 (11.6%)
Infection within prior 2 weeks (n5220) 137 (62.3%)
Antibacterial agents within prior 2 weeks (n5216) 160 (74.1%)
Table 2. Organ systems involved in the primary disease or
condition affecting 214 adult patients who became positive for
yeasts in blood cultures and for whom information on under-
lying conditions was available
Systems are listed in decreasing order of prevalence; each patient is
represented only once.
System or disease type No. of cases
Gastrointestinal tract 48 (22.4%)
Liver/spleen/pancreas/gall bladder 32 (15.0%)
Multiple organ disease 22 (10.3%)
Kidney/urinary tract 18 (8.4%)
Cardiovascular 15 (7.0%)
Lung 15 (7.0%)
Haematological malignancy 13 (6.1%)
Recent abdominal surgery (no other information
given)*
10 (4.7%)
Solid tumour (not involving another system
listed)D
8 (3.7%)
Sepsis 7 (3.3%)
Bone/joint 5 (2.3%)
Brain/meninges 4 (1.9%)
Diabetes 4 (1.9%)
Soft tissue infection 3 (1.4%)
Other condition 10 (4.7%)
*A total of 79/214 patients (36.9%) had undergone recent abdominal
surgery.
DA total of 27/214 patients (12.6%) had solid tumours.
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underlying disease’ in adults with candidaemia mentioned
a very wide range of associated conditions, extending to
alcoholism (8 cases), IV drug abuse (5 cases), road traffic
accidents (3 cases) and cystic fibrosis (2 cases), indicating
that candidaemia can arise in a great number of clinical
situations.
Treatment of candidaemia episodes
Information on antifungal therapy was provided for 195
patients. Of these, 10 died before therapy could be
commenced. A further 19 received no specific antifungal
therapy. Among the 165 patients who were treated with
antifungals, fluconazole was used in 127 patients (65.1%)
overall and in 125 adults, usually at doses of 400 or 800 mg
per day (this detail was added voluntarily on 40 forms).
Liposomal amphotericin B (AmBisome) was used in
29 patients (14.9%) overall (24 were adults). Six patients
were treated with voriconazole, three with amphotericin B
deoxycholate formulation and one with caspofungin.
Among the 125 adult patients who received fluconazole,
72 were infected with C. albicans, 23 with C. glabrata or C.
krusei and 30 with other species. Among the 24 who
received liposomal amphotericin B, the corresponding
breakdown was 13 infected with C. albicans, 7 with C.
glabrata or C. krusei and 4 with another species. The
distributions of species infecting patients were therefore the
same in the patients who received either agent (x
2 test,
P50.44).
Information on the removal of IV lines as part of the
management of candidaemia was provided for 197 patients,
of which line removal was inappropriate in 42 cases, either
because the patient died before intervention or because the
patient had not been catheterized. Among the 155 patients
with candidaemia eligible for line removal, the IV catheter
was removed in 120 (77.4%) of cases.
Mycology
C. albicans was the predominant species among the isolates
from patients with yeast-positive blood cultures, recovered
as the sole isolate in half of the cases (Table 3). C. glabrata
was the second most common species isolated (21%)
followed by C. parapsilosis (12%). None of the latter
isolates proved to be C. orthopsilosis or C. metapsilosis by
PCR/restriction digest. C. dubliniensis alone was isolated
from 7 patients, and in combination with C. glabrata in a
further patient. The prevalences of C. krusei (3 patients)
and C. tropicalis (6 patients) were both very low.
MLST was performed on 152 C. albicans isolates (4 isolates
from one patient had been identified at the originating
hospital but were lost in shipment). Two or more isolates
of the species were obtained from fourteen patients; they
were from clades 1, 2, 3, 4 and 9. In 13 of these patients the
isolates had either the identical DST by MLST or a very
close relative of that DST, within the same clade (Odds
et al., 2007). In the 14th case, 5 of 6 consecutive blood
isolates from a patient were all clade 4; the final isolate,
obtained 7 days after the first isolate and 3 days after the
5th isolate, was clade 1, suggesting strain replacement in
this patient. Table 4 shows the distribution of the C.
albicans isolates between the various clades. Clade 16 is a
new type, found by analysis of a much larger database
(Odds et al., 2007) than was previously published (Tavanti
et al., 2005b).
Previously, C. albicans clade 2 was the most common type
found among isolates from the UK, followed by clade 4
(Tavanti et al., 2005b; Odds et al., 2007). In the present
study clade 1 was the most commonly found, although
clades 2 and 4 were also well represented (Table 4). Within
each clade, particularly clades 1, 2, 4 and 6, a majority of
isolates were so closely related they belonged to the same
clonal cluster by eBURST analysis (Table 4). These clusters
were, however, widely spread among different hospitals,
suggesting the strain types were widespread across the
whole Scottish population, rather than focussed within
individual institutions. Four hospitals each contributed ten
or more C. albicans-infected patients to the study. From 2
hospitals, which contributed 10 and 11 patients, the C.
albicans isolates represented 5 clades, and from 2 others,
which contributed 20 and 21 patients, there were 7 clades
represented among the C. albicans isolates. We interpret
these data as indicating no institutional preponderance of
any particular subtype; nor was such a preponderance
evidenced among hospitals that contributed fewer than
10 cases of C. albicans candidaemia.
Among the 50 patients who were the source of C. glabrata
isolates, 27 STs were found, of which 15 had not been
Table 3. Fungi isolated from blood cultures from 241 patients
with fungaemia
Species Total no. of isolations No. of patients
C. albicans 156 (52.0%) 121 (50.0%)
C. dubliniensis 9 (3.0%) 7 (2.9%)
C. glabrata 68 (22.7%) 50 (20.7%)
C. guilliermondii 10 (3.3%) 7 (2.9%)
C. krusei 3 (1.0%) 3 (1.2%)
C. lusitaniae 6 (2.0%) 6 (2.5%)
C. parapsilosis 35 (11.7%) 28 (11.6%)
C. tropicalis 6 (2.0%) 6 (2.5%)
Other* 7 (2.3%) 2 (0.8%)
MixedD 12 (5.0%)
*Rhodotorula spp. (n55), Prototheca wickerhamii (n51), Cryptococcus
sp. (n51); two patients were each infected only with a Rhodotorula sp.
DTwo or more species isolated in a single blood culture (9 instances)
or in consecutive blood cultures (3 instances): C. albicans+C.
glabrata (6 cases), C. albicans+P. wickerhamii (1 case), C.
guilliermondii+Rhodotorula sp. (1 case), C. dubliniensis+C. glabrata
(1 case), C. guilliermondii+C. parapsilosis (1 case), C. albicans+C.
glabrata+C. parapsilosis (1 case), C. albicans+C. glabrata+
Rhodotorula sp. (1 case).
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were the source of two or more C. glabrata isolates. In six
instances, the identical ST was found in all isolates from the
same patient; in one instance ST 10 was followed by ST 22
from a blood culture 4 days later. Phylogenetic clustering
of large numbers of C. glabrata isolates has not yet been
undertaken. The six isolates of C. tropicalis, from five
hospitals, were all different DSTs.
Antifungal susceptibility testing
The results of antifungal susceptibility testing (Table 5)
showed a considerable prevalence of low azole suscept-
ibility among isolates of C. glabrata. Only one and two C.
albicans isolates fell into the susceptible dose-dependent (S-
DD) MIC range when tested against fluconazole and
itraconazole, respectively, and none were found in the
resistant (R) category. By contrast, more than 60% and
70% of C. glabrata isolates showed reduced susceptibility
(S-DD or R) to fluconazole and itraconazole, respectively.
Even with voriconazole, MICs for 9% of the C. glabrata
isolates were above the ‘susceptible’ breakpoint. Low azole
Table 4. Summary of MLST data for blood isolates of C.
albicans
Clade No. of patients
(%)
Isolate in a single clonal
cluster
No. of
patients
No. of
hospitals
1 34 (26.6) 25 10
2 30 (23.4) 16 7
3 12 (9.4) 0* 0
4 16 (12.5) 12 7
5 2 (1.6) 0 0
6 6 (4.7) 4 4
8 4 (3.1) 0 0
9 5 (3.9) 2 2
11 9 (7.0) 2 2
12 1 (0.8) – –
16 7 (5.5) 3 2
Singletons 2 (1.6) – –
*There were three paired clonal clusters in clade 3; in each case the
pair members came from different hospitals.
Table 5. Susceptibility test results for bloodstream isolates of Candida species
IC50 and IC90 are the concentrations required to inhibit 50 and 90% of isolates, respectively. MIC breakpoints are according to Clinical and
Laboratory Standards Institute method M27-A (NCCLS, 2002). No breakpoints have been set for amphotericin B or caspofungin.
Species (no. tested) Agent MIC (mgm l
”1) No. S-DD or I
(%)
No. R (%)
Range IC50 IC90
C. albicans (153) Amphotericin B 0.063–1.0 0.50 1.0
Flucytosine ¡0.13– .64 ¡0.13 0.25 2 (1.3) 1 (0.7)
Fluconazole ¡0.13–16 0.25 0.50 1 (0.7) 0
Itraconazole ¡0.032–1.0 ¡0.032 ¡0.032 1 (0.7) 1 (0.7)
Voriconazole ¡0.032–1.0 ¡0.032 ¡0.032 0 0
Caspofungin ¡0.032–1.0 0.063 0.13
C. glabrata (66) Amphotericin B 0.063–2.0 0.50 1.0
Flucytosine ¡0.13– .64 ¡0.13 ¡0.13 0 2 (3.0)
Fluconazole ¡0.13– .64 16 32 36 (54.5) 4 (6.1)
Itraconazole ¡0.032– .16 0.50 2.0 27 (40.9) 22 (33.3)
Voriconazole ¡0.032– .8 0.50 1.0 3 (4.5) 3 (4.5)
Caspofungin ¡0.032–1.0 0.25 0.50
C. parapsilosis (35) Amphotericin B ¡0.032–2.0 0.50 1.0
Flucytosine ¡0.13–32 0.13 0.25 0 2 (5.7)
Fluconazole ¡0.13–2.0 0.5 1.0 0 0
Itraconazole ¡0.032–0.25 ¡0.032 0.13 2 0
Voriconazole ¡0.032–0.063 ¡0.032 0.063 0 0
Caspofungin ¡0.032–8.0 1.0 2.0
Other species* (35) Amphotericin B 0.063–2.0 0.50 1.0
Flucytosine ¡0.13–32 ¡0.13 2.0 0 1 (2.9)
Fluconazole ¡0.13– .64 1.0 32 5 (14.3) 2 (5.7)
Itraconazole ¡0.032–0.50 ¡0.032 0.25 8 (22.9) 0
Voriconazole ¡0.032–1.0 0.063 0.5 0 0
Caspofungin ¡0.032–8.0 0.25 2.0
I, Intermediate; R, resistant.
*C. tropicalis (n56), C. guilliermondii (n510), C. krusei (n53), C. lusitaniae (n56), C. dubliniensis (n59), Cryptococcus sp. (n51).
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listed in Table 5, although the species with high azole MICs
recorded included three isolates of C. tropicalis, where the
MICs reflect a common artefactual trailing growth
phenomenon (Arthington-Skaggs et al., 2002; Rex et al.,
1998), and three isolates of C. krusei, which are inevitably
resistant to fluconazole, and for which itraconazole and
voriconazole MICs tend to be higher than for C. albicans.
Five of the Candida guilliermondii isolates also showed
reduced susceptibility to fluconazole and itraconazole.
DISCUSSION
Our study has afforded a very thorough characterization of
candidaemia in Scotland, even though it was set up only as
a pilot survey without the management systems and full
patient documentation that would normally be required
for a multi-centre survey of invasive Candida infection.
Our survey benefited from two factors. The first was the
choice of a yeast-positive blood culture as the inclusion
criterion. Because candidaemia represents an unequivocal
diagnosis of invasive infection (Vazquez & Sobel, 2003)
there can be no diagnostic ambiguity as may be
encountered with other mycoses and other forms of
Candida infection, particularly those involving growth of
a Candida sp. from non-sterile sites. The second is the
friendly community spirit of those involved in diagnostic
microbiology in Scotland, which ensured an enthusiastic
compliance with our request to send on yeasts isolated
from blood. The 300 isolates we obtained from 242 patients
in this survey, and our associated calculation of 4.8 cases
per 100000 population, therefore represents an accurate
minimum estimate of the incidence of candidaemia in this
part of the UK. The true incidence will be higher by an
unknown factor since not all cases of invasive Candida
infection will have been detected by blood culture, and,
notwithstanding the high compliance of the participants,
some positive blood cultures may not have been forwarded
into our survey. Our incidence rate of 4.8 per 100000 is at
the high end of comparable studies from other European
countries (Asmundsdottir et al., 2002; Laupland et al.,
2005; Poikonen et al., 2003; Sandven et al., 2006) with the
exception of Denmark (Arendrup et al., 2005) and lower
than has been recorded in surveys of four regions of the
USA (Hajjeh et al., 2004; Kao et al., 1999).
The incidence rate of 5.9 per 100000 AOBDs described
here compares unfavourably with that of 3.34 described by
Kibbler et al. (2003). Given the similar patient populations,
it is difficult to explain the higher incidence in Scotland,
although it is important to note that the data from England
and Wales are now 7 years old. The proportion of
candidaemia cases recorded on ICUs is markedly lower
in our study (27.9%) compared to the 45% of Kibbler et al.
(2003) and the 35% of Marchetti et al. (2004). In contrast,
our incidence rate of 1.26 cases per 1000 ICU OBDs is
appreciably higher than the rate of 0.98 described by
Blumberg et al. (2001). The differences in cases per
occupied ICU bed day may be explained by differences in
illness severity. Critical care encompasses both level 2 and 3
care, with level 3 patients requiring a greater degree of
respiratory and other organ support. The difference noted
between Scotland and England/Wales may be explained by
the differences in relative distribution of level 2 and 3 beds
within a critical care unit. While Blumberg’s data from the
USA are more than a decade old and refer to surgical ICU
patients only, differences in case mix may also explain the
apparent discrepancy in the rate per patient day. The low
proportion of cases in ICUs also serves to emphasize the
importance of traditional risk factors such as presence of
long lines, administration of broad-spectrum antibiotics
and gastrointestinal surgery, that are increasingly present in
a wide variety of patients outside the ICU setting.
Our data illustrate the difficulties of meaningful definitions
of cases for candidaemia. In all but four instances where
two or more blood culture isolates occurred, the positive
repeat cultures were obtained within 12 days (and mainly
within 7 days) of the first positive culture. However, in one
patient with multiple positive blood cultures over 7 days,
the final C. albicans isolate was unequivocally a different
strain from the previous isolates, which means that case
definitions of candidaemia may need to consider the
species and strain types of isolates as well as the interval
over which blood cultures were positive. In the four
patients where a second blood culture was made from 3 to
6 weeks after the first, the species or strain type isolated was
the same as the first.
The many factors predisposing to candidaemia are well
known and include broad-spectrum antibiotic therapy,
corticosteroid treatment, indwelling IV catheters, total
parenteral nutrition, malignancy, neutropenia and recent
abdominal surgery (Vazquez & Sobel, 2003). All are
represented among the patients in the present study
(Table 2). The predominance of abdominal pathologies
underlying candidaemia in our patient group is empha-
sized by the data in Table 2, which attempts to focus on the
single principle disease condition for which the patient was
hospitalized. In 1969, Cohen et al. cultured samples
aspirated through swallowed, radio-opaque tubes by
healthy human volunteers to determine the carriage of
Candida species in different parts of the gastrointestinal
tract. They found the highest prevalence of positive
aspirates in the lower portion of the tract, reaching 60%
in ileal aspirates and 70% in the colon (Cohen et al., 1969).
In surgical patients at operation in a 1974 study, 47% of
patients carried a Candida sp. in the ileum and 65% in the
colon (Stone et al., 1974). Similar surveys have not been
conducted in more recent years, but these early data
suggest that the typical frequencies of carriage found in oral
and rectal or faecal samples underestimate the true
prevalence of yeasts in the lower intestine. Diseases or
surgical interventions that affect the intestine are therefore
highly likely to create a conduit for yeasts to enter the
bloodstream. Typical chemotherapeutic interventions in
haematological practice also lower the barrier integrity of
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bloodstream (Blijlevens et al., 2002).
The most recent recommendations for treatment of
candidaemia include removal of IV catheters (this was
done in 77% of our catheterized patients) as well as
systemic antifungal therapy (Pappas et al., 2004).
Fluconazole was the agent most widely used for treatment.
However, our susceptibility testing data show that reduced
susceptibility and resistance to fluconazole are common
among isolates of C. glabrata, and it may prove simpler in
clinical practice to use an alternative agent to treat C.
glabrata candidaemia. C. glabrata isolates remain generally
susceptible to amphotericin B, flucytosine and caspofungin
(Table 5). When an isolate is found to be in the S-DD
category, fluconazole dosing should be increased in an
effort to achieve the AUC (area under the curve)/MIC ratio
of 25 shown to be needed for eradication of infection in
experimental pharmacodynamic studies (Andes, 2004;
Andes & van Ogtrop, 1999). Our susceptibility data
(Table 5) are similar to those of other studies published
in recent years, and confirm low or negligible levels of
antifungal resistance among C. albicans and C. parapsilosis
isolates but a high level of reduced azole susceptibility
among C. glabrata isolates (Diekema et al., 2002; Pfaller
et al., 2002).
The prevalence of C. dubliniensis among our bloodstream
isolates is worthy of attention. This species is often thought
of as associated mainly with oral infections. However, it has
been regularly reported as a cause of candidaemia since
1999 (Chan-Tack, 2005; Kibbler et al., 2003; Meis et al.,
1999; Tortorano et al., 2004) and one study even identified
C. dubliniensis in over 16% of cases of candidaemia
(Fotedar & Al Hedaithy, 2003). Our own prevalence of C.
dubliniensis (2.9%) is slightly higher than that of a
previous, smaller UK survey (Kibbler et al., 2003), and it
exceeded that of C. krusei and even C. tropicalis among
candidaemia patients in Scotland. The prevalences of the
three species found as major causes of candidaemia in
Scotland are very similar to those reported in the 2003
Health Protection Agency (HPA) communicable disease
surveillance survey of candidaemia in England, Wales and
Northern Ireland (HPA, 2004). Recalculated to ignore
yeasts submitted without identification, the HPA data
show the prevalence of C. albicans as 60.0% in England
and Wales versus 50.0% in our study, C. glabrata 18.1%
versus 20.7% and C. parapsilosis 12.1% versus 11.6%.
Between the surveys, it can be concluded that C. albicans,
C. glabrata and C. parapsilosis currently account for more
than 80% of candidaemias in the UK, and that C. tropicalis
has entirely lost its former position (Odds, 1988) as the
second most common causative species.
C. parapsilosis is well recognized as a particularly common
cause of candidaemia in neonates (Levy et al., 1998;
Rangel-Frausto et al., 1999; Sandven, 2000). In our patient
cohort there were only four neonates with candidaemia;
three were infected with C. albicans and one with Candida
lusitaniae. Among the other nine children aged 5 or less,
three were infected with C. parapsilosis, and one with a
mixture of C. albicans, C. glabrata and C. parapsilosis. The
remainder were infected with C. albicans. The overall
prevalence of C. parapsilosis among all species isolated
from children under five was therefore 33.3%. However,
the number of paediatric cases was relatively so small that
the association of C. parapsilosis with candidaemia in
neonates and infants would not explain the overall high
prevalence of the species even in the adult population.
Recent surveys of candidaemia from Spain and Italy have
shown prevalences of C. parapsilosis between 20 and 40%
(Almirante et al., 2005; Cuenca-Estrella et al., 2002a; Marco
et al., 2003; Pema ´n et al., 2005; San Miguel et al., 2005).
This species is clearly emerging as a significant cause of
candidaemia in Europe. A retrospective and unpublished
PCR survey of 100 of our culture collection of isolates
originally identified as C. parapsilosis revealed 6 were in fact
C. orthopsilosis and 1 was C. metapsilosis. We were therefore
surprised that none of the 28 isolates identified phenoty-
pically in the present study was an example of either of the
new species.
Strain typing of C. albicans and C. glabrata isolates by
MLST confirmed previous evidence that individual
patients usually carry a single strain type of a species in
repeated isolates (Odds et al., 2006). However, it is notable
that single counter-examples were found, in two patients,
each infected with one of the two species typed, showing
that strain replacement is possible even in repeated blood
cultures from patients with candidaemia. It is, perhaps,
notable that 7 of the 12 patients with mixed species
infections detected in blood cultures had undergone
surgical procedures involving the bowel; as already stated,
the significance of the bowel as a source for haematogenous
dissemination of commensal Candida species cannot be
underestimated.
Many of the C. albicans isolates collected from different
hospitals across the whole extent of Scotland were found to
be closely related by MLST, sometimes extremely so. This
suggests that certain C. albicans strain types are more likely
than others to be associated with human carriage and
disease than others. The four main C. albicans strain clades
described from all sources in previous studies (Blignaut
et al., 2002; Odds et al., 2006; Pujol et al., 2002; Soll &
Pujol, 2003) remain the most commonly encountered in
candidaemia in our study, and these and others were found
across the range of hospitals submitting isolates. This
indicates that the strain types found in candidaemia most
probably reflect the same distribution as found in
commensal isolates, and that hospitals do not serve as
endemic foci of particular C. albicans strain types.
We did not attempt to collect data on mortality associated
with candidaemia, since this study used a laboratory-based
criterion for inclusion and the clinical information
available was clearly collected with difficulty for some
cases. A future, prospective study with dedicated staff able
F. C. Odds and others
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candidaemia and other types of invasive Candida infection
would allow assessment of mortality and of other
parameters relevant to the switch of Candida species from
commensals to pathogens. This pilot study has shown that
the incidence of candidaemia in Scotland is high, and the
occurrence of C. glabrata as the second most common
causative species, with a high proportion of isolates show-
ing reduced azole susceptibility, indicating the potential
value of continued future surveillance. Clinicians need to
remain alert to the wide breadth of debilitating conditions
in which candidaemia can arise.
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